{
    "name": "peginterferon beta-1a",
    "comment": "Rx",
    "other_names": [
        "Plegridy"
    ],
    "classes": [
        "Immunomodulators",
        "Multiple Sclerosis Treatments"
    ],
    "source": "https://reference.medscape.com/drug/plegridy-peginterferon-beta-1a-999928",
    "pregnancy": {
        "common": [
            "There is pregnancy exposure registry that monitors pregnancy outcomes in women exposed to drug during pregnancy; encourage patients to enroll by calling 1-866-810-1462 or visiting ",
            "Data from large population-based cohort study, as well as other published studies over several decades, have not identified drug-associated risk of major birth defects with use of interferon beta products during early pregnancy; findings regarding potential risk for low birth weight or miscarriage with use of interferon beta products in pregnancy have been inconsistent; in a study in pregnant monkeys, administration of interferon beta during pregnancy resulted in an increased rate of abortion"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Limited published literature has described the presence of interferon beta-1a products in human milk at low levels; there are no data on effects of interferon beta-1a on milk production",
            "Consider developmental and health benefits of breastfeeding along with motherâ€™s clinical need for drug and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Depression, suicidal ideation, and suicide may occur; advise patients to report immediately any symptom of depression and consider discontinuing if depression occurs",
                "Congestive heart failure and/or cardiomyopathy reported (7% in both peginterferon beta-1a- and placebo-treated patients)",
                "Decreased peripheral blood counts reported in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia; monitor for symptoms of infections, bleeding, and anemia; monitor CBC counts, differential WBC counts, and platelet counts",
                "Autoimmune disorders of multiple target organs, including idiopathic thrombocytopenia, hyper- and hypothyroidism reported",
                "Severe hepatic injury, including hepatitis, autoimmune hepatitis, and rare cases of severe hepatic failure, reported; cases of noninfectious hepatitis in postmarketing setting also reported; monitor patients for signs and symptoms of hepatic injury",
                "In patients with renal impairment, monitor for adverse reactions because of increased systemic exposure",
                "Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, reported; some cases have been reported several weeks to years after starting interferon beta products; discontinue therapy if clinical symptoms and laboratory findings consistent with TMA occur, and manage as clinically indicated"
            ],
            "specific": [
                {
                    "type": "Serious allergic reactions",
                    "description": [
                        "Serious allergic reactions (eg, angioedema, urticaria) reported",
                        "Treat allergic reaction appropriately and promptly with antihistamines or corticosteroids",
                        "Discontinue if a serious allergic reaction occurs",
                        "Protective rubber cover of prefilled syringe for IM administration contains natural rubber latex; avoid IM use in patients that allergic or sensitive to latex; safety of prefilled syringes in latex-sensitive individuals not studied"
                    ]
                },
                {
                    "type": "Injection site reactions",
                    "description": [
                        "Injection site reactions, including injection site necrosis, can occur with the use of interferon beta products; in controlled clinical trials, injection site reactions (eg, injection site pain, bruising or erythema) reported; reactions included injection site inflammation (6%), injection site pain (8%), injection site mass (<1%), nonspecific reactions",
                        "Injection site abscesses and cellulitis and injection site necrosis reported in postmarketing setting with interferon beta products; some cases required treatment with hospitalization for surgical drainage and intravenous antibiotics",
                        "Periodically evaluate patient understanding and use of aseptic self-injection techniques and procedures, particularly if injection site necrosis has occurred",
                        "Whether to discontinue therapy following a single site of necrosis is dependent on extent of necrosis; for patients who continue therapy after injection site necrosis has occurred, avoid administration of the drug into the affected area until it is fully healed; if multiple lesions occur, change injection site or discontinue therapy until healing occurs"
                    ]
                },
                {
                    "type": "Hepatic injury",
                    "description": [
                        "Severe hepatic injury, including hepatitis, autoimmune hepatitis, and rare cases of severe hepatic failure, reported ",
                        "Elevated hepatic enzymes and hepatic injury reported; recurred in some patients upon rechallenge",
                        "Monitor for signs and symptoms of hepatic injury"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Chills",
            "percent": "36"
        },
        {
            "name": "Headache",
            "percent": "36-41"
        },
        {
            "name": "Pain",
            "percent": "22"
        },
        {
            "name": "Injection site pain",
            "percent": "11"
        },
        {
            "name": "Injection site erythema",
            "percent": "25-62"
        },
        {
            "name": "Influenza like illness",
            "percent": "47"
        },
        {
            "name": "Pyrexia",
            "percent": "45"
        },
        {
            "name": "Headache",
            "percent": "41"
        },
        {
            "name": "Chills",
            "percent": "17-27"
        },
        {
            "name": "Injection site pain",
            "percent": "15"
        },
        {
            "name": "Asthenia",
            "percent": "13"
        },
        {
            "name": "Injection site pruritus",
            "percent": "13"
        },
        {
            "name": "Injection site erythema",
            "percent": "2"
        },
        {
            "name": "Body temperature increased",
            "percent": "6"
        },
        {
            "name": "ALT increased",
            "percent": "6"
        },
        {
            "name": "Pain",
            "percent": "5"
        },
        {
            "name": "AST increased",
            "percent": "4"
        },
        {
            "name": "Pruritus",
            "percent": "4"
        },
        {
            "name": "Hyperthermia",
            "percent": "4"
        },
        {
            "name": "Gamma",
            "percent": "3"
        },
        {
            "name": "glutamyl",
            "percent": "3"
        },
        {
            "name": "transferase increased",
            "percent": "3"
        },
        {
            "name": "Injection site edema",
            "percent": "3"
        },
        {
            "name": "Injection site warmth",
            "percent": "2"
        },
        {
            "name": "Injection site hematoma",
            "percent": null
        },
        {
            "name": "Injection site rash",
            "percent": null
        }
    ]
}